COGTHIGH SIGNALFINANCIAL10-K

COGT experienced massive balance sheet expansion with total liabilities surging 321% to $301.2M while cash increased 218% to $312.0M, indicating a significant financing event, though operating losses deepened by 29%.

The dramatic increase in both cash and liabilities suggests a major debt or convertible financing round, supported by the new language about convertible notes creating operational constraints. While the company secured substantial liquidity, the worsening operating cash flow burn of $264.4M and larger net losses signal accelerating cash consumption that could pressure the runway despite the capital raise.

Comparing 2026-02-17 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

COGT's financials show a transformational period with total assets nearly tripling to $938M driven by a major financing that boosted cash to $312M while adding $230M in new liabilities. Despite this capital infusion, operational performance deteriorated with net losses widening 29% to $329M and operating cash burn increasing 27% to $264M, indicating the company is spending aggressively on development while facing mounting cash consumption pressures. The 42% increase in outstanding shares from 114M to 162M suggests significant equity dilution accompanied the financing, creating a complex risk-reward profile for existing shareholders.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+320.7%
$71.6M$301.2M

Liabilities grew 320.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
+217.8%
$98.2M$312.0M

Cash position surged 217.8% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+207.1%
$296.5M$910.4M

Current assets grew 207.1% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+185.9%
$327.9M$937.6M

Asset base grew 185.9% — expansion through organic growth, acquisitions, or capital deployment.

Capital Expenditure
Cash Flow
+171.2%
$573K$1.6M

Capital expenditure jumped 171.2% — major investment cycle underway; assess returns on deployment.

Stockholders Equity
Balance Sheet
+148.3%
$256.3M$636.4M

Equity base grew 148.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
-28.6%
-$255.9M-$328.9M

Net income declined 28.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-27.3%
-$207.8M-$264.4M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Operating Income
P&L
-20.8%
-$275.9M-$333.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Accounts Receivable
Balance Sheet
+19.9%
$1.7M$2.0M

Receivables grew 19.9% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-25
ADDED
As of February 13, 2026, there were 162,308,820 shares of the registrant s Common Stock, $0.001 par value per share, outstanding.
The commercial success of any future approved drugs, including bezuclastinib, will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.
If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates or discover new product candidates on our intended timelines, if at all.
We may have difficulty building our sales, marketing and distribution infrastructure.
We may require additional capital to finance our planned operations.
+7 more — sign up free →
REMOVED
As of February 21, 2025, there were 113,850,090 shares of the registrant s Common Stock, $0.001 par value per share, outstanding.
If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates or discover new product candidates.
All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy and plans, and objectives of management for future operations, are forward-looking statements.
We are developing bezuclastinib to treat patients living with Non-Advanced Systemic Mastocytosis ( Non-AdvSM ), Advanced Systemic Mastocytosis ( AdvSM ) and GIST.
We also have an ongoing Phase 1 study of our novel internally developed FGFR2 inhibitor, CGT4859.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →